148 related articles for article (PubMed ID: 12412165)
1. Prognostic significance of thymidine kinase activity in bladder carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Kamoi K; Miki T
Cancer; 2002 Nov; 95(10):2120-5. PubMed ID: 12412165
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma.
Mizutani Y; Wada H; Fukushima M; Yoshida O; Nakanishi H; Li YN; Miki T
Cancer; 2004 Feb; 100(4):723-31. PubMed ID: 14770427
[TBL] [Abstract][Full Text] [Related]
3. Significance of thymidine kinase activity in renal cell carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Nakao M; Miki T
J Urol; 2003 Feb; 169(2):706-9. PubMed ID: 12544347
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of a combination of thymidylate synthase and dihydropyrimidine dehydrogenase activities in grades 1 and 2 superficial bladder cancer.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Bonavida B; Kawauchi A; Miki T
Oncol Rep; 2002; 9(2):289-92. PubMed ID: 11836594
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
Mizutani Y; Okada Y; Terachi T; Yoshida O
J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
10. The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Kawauchi A; Nakao M; Miki T
Cancer; 2003 Aug; 98(4):730-6. PubMed ID: 12910516
[TBL] [Abstract][Full Text] [Related]
11. Expression of platelet-derived endothelial cell growth factor in bladder carcinoma.
Mizutani Y; Okada Y; Yoshida O
Cancer; 1997 Mar; 79(6):1190-4. PubMed ID: 9070497
[TBL] [Abstract][Full Text] [Related]
12. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
13. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer.
Divrik RT; Sahin A; Altok M; Unlü N; Zorlu F
J Urol; 2007 Sep; 178(3 Pt 1):802-6; discussion 806. PubMed ID: 17632171
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters.
Lopez-Beltran A; Luque RJ; Alvarez-Kindelan J; Quintero A; Merlo F; Requena MJ; Montironi R
Am J Clin Pathol; 2004 Sep; 122(3):444-52. PubMed ID: 15362377
[TBL] [Abstract][Full Text] [Related]
15. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ.
Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M
Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389
[TBL] [Abstract][Full Text] [Related]
16. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
17. Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients.
Zhang J; Jia Q; Zou S; Zhang P; Zhang X; Skog S; Luo P; Zhang W; He Q
Oncol Rep; 2006 Feb; 15(2):455-61. PubMed ID: 16391869
[TBL] [Abstract][Full Text] [Related]
18. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder.
May M; Nitzke T; Helke C; Vogler H; Hoschke B
Scand J Urol Nephrol; 2004; 38(3):231-5. PubMed ID: 15204377
[TBL] [Abstract][Full Text] [Related]
19. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
20. [Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas].
Zhan J; Tang XD
Ai Zheng; 2002 Nov; 21(11):1212-6. PubMed ID: 12526218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
